WO2014140322A1 - Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire - Google Patents
Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire Download PDFInfo
- Publication number
- WO2014140322A1 WO2014140322A1 PCT/EP2014/055179 EP2014055179W WO2014140322A1 WO 2014140322 A1 WO2014140322 A1 WO 2014140322A1 EP 2014055179 W EP2014055179 W EP 2014055179W WO 2014140322 A1 WO2014140322 A1 WO 2014140322A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- composition
- antibody composition
- antigen
- isoforms
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 202
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 108010029485 Protein Isoforms Proteins 0.000 title abstract description 147
- 102000001708 Protein Isoforms Human genes 0.000 title abstract description 147
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract description 38
- 238000005194 fractionation Methods 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims description 103
- 239000000427 antigen Substances 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 68
- 102000036639 antigens Human genes 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 40
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 38
- 102000004169 proteins and genes Human genes 0.000 claims description 38
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 239000012636 effector Substances 0.000 claims description 32
- 230000009261 transgenic effect Effects 0.000 claims description 29
- 238000004587 chromatography analysis Methods 0.000 claims description 28
- 238000011098 chromatofocusing Methods 0.000 claims description 27
- 238000010828 elution Methods 0.000 claims description 27
- 238000012986 modification Methods 0.000 claims description 27
- 108020003175 receptors Proteins 0.000 claims description 27
- 230000004048 modification Effects 0.000 claims description 26
- 238000004255 ion exchange chromatography Methods 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 23
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 23
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 22
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 22
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004899 c-terminal region Anatomy 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 15
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 15
- 230000000295 complement effect Effects 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 238000006073 displacement reaction Methods 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 9
- 210000002865 immune cell Anatomy 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 7
- 206010060935 Alloimmunisation Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 230000007246 mechanism Effects 0.000 abstract description 3
- 238000009175 antibody therapy Methods 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 description 42
- 239000000872 buffer Substances 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 36
- 238000005277 cation exchange chromatography Methods 0.000 description 35
- 239000011347 resin Substances 0.000 description 29
- 229920005989 resin Polymers 0.000 description 29
- 230000004044 response Effects 0.000 description 26
- 239000002253 acid Substances 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 230000002378 acidificating effect Effects 0.000 description 17
- 108010073807 IgG Receptors Proteins 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 241000196324 Embryophyta Species 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 230000004481 post-translational protein modification Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- 238000001155 isoelectric focusing Methods 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 8
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 8
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000003957 anion exchange resin Substances 0.000 description 8
- 230000002489 hematologic effect Effects 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 150000001450 anions Chemical class 0.000 description 7
- 230000001174 ascending effect Effects 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 239000012149 elution buffer Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000003729 cation exchange resin Substances 0.000 description 6
- 229960001231 choline Drugs 0.000 description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229920006037 cross link polymer Polymers 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 4
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 102100029198 SLAM family member 7 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000006240 deamidation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000033581 fucosylation Effects 0.000 description 4
- 101150023212 fut8 gene Proteins 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101710203794 GDP-fucose transporter Proteins 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 102100022337 Integrin alpha-V Human genes 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 150000004676 glycans Chemical group 0.000 description 3
- 101150106565 gmd gene Proteins 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000006317 isomerization reaction Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- -1 sulfopropyl Chemical group 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 235000008979 vitamin B4 Nutrition 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000012804 EPCAM Human genes 0.000 description 2
- 101150084967 EPCAM gene Proteins 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 2
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 2
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001046677 Homo sapiens Integrin alpha-V Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001590997 Moolgarda engeli Species 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 101150057140 TACSTD1 gene Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
- 229950007843 bavituximab Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 229940023913 cation exchange resins Drugs 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920000867 polyelectrolyte Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229950010699 roledumab Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000012784 weak cation exchange Methods 0.000 description 2
- LXBIFEVIBLOUGU-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-KVTDHHQDSA-N 0.000 description 1
- BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229940126609 CR6261 Drugs 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100342815 Caenorhabditis elegans lec-1 gene Proteins 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000016917 Complement C1 Human genes 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940126626 Ektomab Drugs 0.000 description 1
- 102100021771 Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101710123022 Integrin alpha-V Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- BKZOUCVNTCLNFF-UHFFFAOYSA-N Lonomycin Natural products COC1C(C)C(C2(C)OC(CC2)C2(C)OC3(OC(C(C)C(OC)C3)C(C)C3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)C)CC2)OC1C1OC(C)(O)C(C)C(OC)C1C BKZOUCVNTCLNFF-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229910021205 NaH2PO2 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000207746 Nicotiana benthamiana Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000712910 Pichinde mammarenavirus Species 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000201788 Staphylococcus aureus subsp. aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 229950004283 actoxumab Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000000959 ampholyte mixture Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229950003145 apolizumab Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229950000103 atorolimumab Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229950008086 bezlotoxumab Drugs 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229950006754 cedelizumab Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229950002334 clenoliximab Drugs 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229950009760 epratuzumab Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229950005562 exbivirumab Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 229950011078 foravirumab Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229950002140 futuximab Drugs 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 229950005173 libivirumab Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229950008897 morolimumab Drugs 0.000 description 1
- 229960001521 motavizumab Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950002610 otelixizumab Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229950010626 pagibaximab Drugs 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229950003570 panobacumab Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229950003700 priliximab Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229950002786 rafivirumab Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229950005854 regavirumab Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 229950004951 sevirumab Drugs 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229950011267 solitomab Drugs 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229950001788 tefibazumab Drugs 0.000 description 1
- 229950000301 teneliximab Drugs 0.000 description 1
- 229950010127 teplizumab Drugs 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229950005082 tuvirumab Drugs 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229950004362 urtoxazumab Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000012608 weak cation exchange resin Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Definitions
- Novel Drugs comprising an Antibody Composition Enriched with Majority Charge Isoform
- the present invention is in the technical field of antibody therapies involving a target cell killing mechanism by ADCC. It relates to purified antibody compositions, obtained by chromatographic fractionation of the different charge isoforms naturally present in an antibody composition and grouping of one or more chromatographic fractions corresponding to the major peak of the chromatogram, the monoclonal antibody composition as well as obtained being enriched in said majority peak, which represents at least 85% of the chromatogram of the composition obtained, for use as a medicament.
- Prior art relates to purified antibody compositions, obtained by chromatographic fractionation of the different charge isoforms naturally present in an antibody composition and grouping of one or more chromatographic fractions corresponding to the major peak of the chromatogram, the monoclonal antibody composition as well as obtained being enriched in said majority peak, which represents at least 85% of the chromatogram of the composition obtained, for use as a medicament.
- an antibody composition is inherently heterogeneous. Indeed, the antibody compositions used in therapy are produced in biological systems (cells, animals or transgenic plants), in which the proteins in general, and therefore the antibodies in particular, are subjected to a number of post-modification modifications. translational (enzymatic modifications or degradations), which will vary from one antibody molecule to another and thus generate micro-heterogeneity within the antibody composition produced.
- Antibodies are glycoproteins consisting of four polypeptide chains: two heavy chains (called “H” for “heavy”) generally identical and two light chains (called “L” for “light”) generally identical associated by a variable number of disulfide bridges and non-covalent interactions. These chains form a Y-shaped structure, the heavy chain contributing to the trunk of the Y and half of each arm of the Y, the light chain contributing to half of each arm of the Y.
- Each light chain consists of a constant domain ( C L ) and a variable domain (V L ); the heavy chains are composed of a variable fragment (V H ) and 3 or 4 constant fragments (Cm-C H 3 or Cm) according to the isotype of the antibody (the IgG comprise 3 constant fragments Cm to Cm) -
- the association of the light chain (V L + C L ) and the heavy chain domains V H and Cm form the Fab fragment, the associated VL and VH domains being responsible for the recognition of the antigen.
- the constant domains (C H 2 and Cm) or (C H 2 -C H4) of the two heavy chains form the constant Fc fragment.
- the antibodies are known to be subjected to the following post-translational modifications: terminal modifications of heavy or light chains, glycosylation of the Fc (and possibly Fab) part, deamidation, isomerization, oxidation, fragmentation, and aggregation (see Vlasak et al. 2008).
- the glycosylation of the constant Fc part of the antibodies is now well known to strongly influence many biological properties of the antibody: in vivo half-life (see Wright et al. induce an ADCC response (cytotoxic cell response dependent on the antibody, see Satoh et al. 2006, Presta et al. 2006), a CDC response (complement-dependent cytotoxic response, see Wright et al. 1994, Presta et al. 2006). ), etc.
- the content of the antibody composition in fucosylated glycan forms is today known to very strongly affect the ability of the composition to induce an ADCC response in vivo.
- Khawli et al-2010 and Vogel et al-201 1 describe the separation by chromatographic techniques using a cation exchange resin of the acidic, predominant, and basic isoforms of a monoclonal antibody composition used passive immunotherapy; the analysis of post-translational modifications leading to the existence of several isoforms; as well as the study of the pharmacokinetic properties and certain functional properties of three purified fractions (acid, majority and basic).
- the chromatogram of the native composition shows, as always, a majority peak, surrounded by peaks comprising acidic isoforms and peaks comprising basic isoforms.
- the identified post-translational modifications include the reduction of some disulfide bridges (Khawli et al-2010), glycations (Khawli et al-2010, Vogel et al-201 1), dehydration (Khawli et al-2010, Vogel et al. al-201 1), the cleavage of C-terminal lysines of the heavy chains (Khawli et al-2010, Vogel et al-201 1), the presence of aggregates (Gandhi et al-201 1), oxidation phenomena (Gandhi et al-201 1).
- EP1308456 and WO2004 / 024866 describe chromatographic methods for removing acidic variants of a monoclonal antibody composition, without the effectiveness of the effector properties of the composition before and after purification being tested.
- WO201 1/009623 discloses a chromatographic method for removing acidic variants or basic variants of a monoclonal antibody composition, without the effector properties of the composition before and after purification being tested.
- the method described in this document eliminates only one type of variant and only the elimination of acid variants is actually implemented.
- a fraction purified by chromatography, enriched in the major charge isoform of an antibody composition has a significantly higher capacity to induce an effector response via the CD16 receptor by the effector cells expressing this receptor.
- a purified fraction enriched in the major charge isoform of an antibody composition makes it possible to induce a stronger ADCC response and a stronger CDC response in vivo, and thus to increase the clinical and / or decrease the doses administered, thus limiting the side effects.
- the present invention therefore relates to a monoclonal antibody composition obtainable by a process comprising:
- step b) fractionating the composition obtained in step a) by chromatography, and c) the grouping of one or more chromatographic fractions obtained in step b), corresponding to the major peak of the chromatogram, the monoclonal antibody composition thus obtained being enriched in said majority peak, the latter representing at least 85%, advantageously at least 86%, at least 87%, at least 88%, at least 89%, more preferably at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, minus 95%, at least 96%, at least 97%, at least 98%, at least 98,5%, at least 99%, or at least 99,5% of the chromatogram of the composition obtained in step c) ,
- step b) is carried out by fractionation of the composition obtained in step a) by conventional ion exchange chromatography, by chromatofocusing, or by hydrophobic interaction chromatography.
- the ion exchange chromatography uses one of the following eluting means:
- compositions for use as a medicament at least 95%, advantageously at least 96%, at least 97%, at least 98%, or even at least 98.5%, at least 99%, or at least less than 99.5% of the heavy chains of the antibodies present in the composition do not comprise a C-terminal lysine residue.
- the invention also relates to a monoclonal antibody composition, wherein at least 95%, preferably at least 96%, at least 97%, at least 98%, or at least 98.5%, at least 99%, or at least less than 99.5% of the heavy chains of the antibodies present in the composition do not comprise a C-terminal lysine residue for use as a medicament.
- the antibody is advantageously directed against a non-ubiquitous antigen present on healthy donor cells, an antigen of a cancer cell, or an antigen of an infected cell. by pathogen.
- the antibody is an anti-Rhesus D antibody and the composition and intended for the prevention of alloimmunisation in Rh-negative individuals.
- the antibody is directed against an antigen of a cancer cell and the composition and intended for the treatment of a cancer, the antibody is directed against an antigen of a cell infected with a pathogen and the composition and intended for the treatment of an infection by said pathogenic organism,
- the antibody is directed against an antigen of an immune cell and the composition for the treatment of an autoimmune disease.
- the antibody comprises a modification of the Fc fragment increasing its binding to the Fc ⁇ RIII receptor and its effector properties via the Fc ⁇ RIII receptor.
- the composition for use as a medicament according to the invention may in particular comprise mutations in the Fc fragment increasing its binding to the Fc ⁇ RIII receptor and / or a low fucose content.
- the antibodies present in the composition have on their N-glycosylation sites of the Fc fragment glycan structures of biantenné type, with a fucose content of less than 65%.
- the antibody comprises a modification of the Fc fragment increasing its binding to the C1 protein and its effector properties via the complement.
- the present invention also relates to the use of a chromatographic fractionation step to increase the ability of a monoclonal antibody composition directed against a given antibody to induce antibody-dependent cellular cytotoxicity (ADCC) of target cells expressing said antigen by the effector cells of the immune system expressing the Fc ⁇ RIII receptor (CD16).
- ADCC antibody-dependent cellular cytotoxicity
- the present invention also relates to the use of a chromatography fractionation step for increasing the ability of a monoclonal antibody composition directed against a given antibody to induce complement-dependent cytotoxicity (CDC) of target cells expressing said antigen by the complement.
- CDC complement-dependent cytotoxicity
- FIG. 1 Chromatograms obtained for three separations by chromatofocusing of an anti-CD20 antibody composition (anion exchange resin (Mono TM P column marketed by GE Life Sciences) with elution by a descending gradient of pH (9.5 at 8.0 using two buffers: buffer A (25 mM diethanolamine), buffer B (polybuffer 96 + pharmalyte 8-10.5))
- the antibody composition was desalted, and 20 mg was injected onto the column . Fractions of 2 ml were collected. Fractions 33 to 50 were collected for analysis.
- FIG. 1 Chromatograms of the CEX purified anti-CD20 antibody composition.
- A Chromatogram of the anti-CD20 antibody composition before purification.
- B Chromatogram of the composition formed by assembling fractions 1 to 20 corresponding to the major peak of the chromatogram before separation (A). The percentage of the different peaks are indicated.
- FIG. 4 Binding to CD16 (Biacore) purified fractions by cation exchange chromatography. The CD16 binding of each sample is expressed as a percentage of the CD16 binding of a reference sample
- the CD16 activity (secretion of IL-2 by Jurkat CD16 cells) of each sample is expressed as a percentage of the CD16 activity of a reference sample.
- the present invention therefore relates to a monoclonal antibody composition obtainable by a process comprising:
- step b) fractionating the composition obtained in step a) by chromatography
- step c) the grouping of one or more chromatographic fractions obtained in step b), corresponding to the major peak of the chromatogram, the monoclonal antibody composition thus obtained being enriched in said majority peak, the latter representing at least 85%, advantageously at least 86%, at least 87%, at least 88%, at least 89%, more preferably at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, 95%, at least 96%, at least 97%, at least 98%, at least 98,5%, at least 99%, or at least 99.5% of the chromatogram of the composition obtained in stage c),
- a monoclonal antibody composition is produced from a cell clone, a transgenic animal or a transgenic plant.
- antibody or “immunoglobulin” is meant a molecule comprising at least one binding domain to a given antigen and a constant domain comprising a Fc fragment capable of binding to FcR receptors.
- an antibody is composed of 4 polypeptide chains: 2 heavy chains and 2 light chains linked together by a variable number of disulfide bridges providing flexibility to the molecule.
- Each light chain consists of a constant domain (CL) and a variable domain (VL); the heavy chains being composed of a variable domain (VH) and 3 or 4 constant domains (CH1 to CH3 or CH1 to CH4) according to the isotype of the antibody.
- VH variable domain
- CH1 to CH3 or CH1 to CH4 constant domains
- antibodies consist of only two heavy chains, each heavy chain comprising a variable domain (VH) and a constant region.
- Variable domains are involved in antigen recognition, while constant domains are involved in the biological, pharmacokinetic and effector properties of the antibody.
- the constant domains are characterized by an amino acid sequence very close to one antibody to another, characteristic of the species and the isotype, with possibly somatic mutations.
- the Fc fragment is naturally composed of the constant region of the heavy chain excluding the CH1 domain, that is to say the lower hinge region and the constant CH2 and CH3 or CH2 to CH4 domains (depending on the isotype ).
- the complete Fc fragment is composed of the C-terminal portion of the heavy chain from the cysteine residue at position 226 (C226), the numbering of amino acid residues in the Fc fragment being throughout the present invention. description that of the EU index described in Edelman et al. 1969 and Kabat et al. 1991.
- the corresponding Fc fragments of other types of immunoglobulins can be easily identified by those skilled in the art by sequence alignments.
- the Fc fragment is glycosylated at the CH2 domain with the presence, on each of the 2 heavy chains, of a / V-glycan linked to the asparagine residue at position 297 (Asn 297).
- the following binding domains, located in the Fc, are important for the biological properties of the antibody:
- FcRn receptor binding domain involved in the pharmacokinetic properties (in vivo half-life) of the antibody:
- C1 complement protein binding domain q involved in the CDC response (for "complement dependent cytotoxicity"): located in the CH2 domain;
- the Fc fragment of an antibody may be natural, as defined above, or may have been modified in various ways, provided that it comprises a FcR receptor binding domain (Fc ⁇ R receptors for IgG) functional, and preferably a functional FcRn receptor binding domain.
- the modifications may include deleting certain portions of the Fc fragment, provided that it contains a functional FcR receptor binding domain (Fc ⁇ R receptors for IgG), and preferably a functional FcRn receptor binding domain.
- the modifications may also include different amino acid substitutions that may affect the biological properties of the antibody, provided that it contains a functional FcR receptor binding domain, and preferably a functional FcRn receptor binding domain.
- the antibody when it is an IgG, it may comprise mutations intended to increase the binding to the Fc ⁇ RIII receptor (CD16), as described in WO00 / 42072, Shields et al-2001, Lazar et al. 2006, WO2004 / 029207, WO / 2004063351, WO2004 / 074455. Mutations to increase FcRn receptor binding and thus in vivo half-life may also be present, as described for example in Shields et al-2001, Dall'Acqua et al. 2002, Hinton et al. 2004, Dall Acqua et al.
- “monoclonal antibody” or “monoclonal antibody composition” is meant a composition comprising antibody molecules having identical and unique antigenic specificity.
- the antibody molecules present in the composition are likely to vary in their post-translational modifications, and in particular in their glycosylation structures or their isolating point, but have all been coded by the same heavy and light chain sequences and therefore have, before any modification post-translational, the same protein sequence.
- Certain protein sequence differences, related to post-translational modifications eg cleavage of C-terminal heavy chain lysine, deamidation of asparagine residues and / or isomerization of aspartate residues
- the monoclonal antibody present in the composition used as a medicament in the context of the invention may advantageously be chimeric, humanized, or human. Indeed, this makes it possible to avoid the immune reactions of the patient against the administered antibody.
- chimeric antibody an antibody which contains a naturally occurring variable (light chain and heavy chain) derived from an antibody of a given species in association with the constant light chain and heavy chain regions of an antibody of a heterologous species to said given species.
- the monoclonal antibody composition for use as a medicament according to the invention comprises a chimeric monoclonal antibody, it comprises human constant regions.
- a chimeric antibody can be prepared using genetic recombination techniques well known to those skilled in the art.
- the chimeric antibody may be made by cloning for the heavy chain and the light chain a recombinant DNA comprising a promoter and a sequence coding for the variable region of the non-human antibody, and a sequence coding for the constant region of the a human antibody.
- a recombinant DNA comprising a promoter and a sequence coding for the variable region of the non-human antibody, and a sequence coding for the constant region of the a human antibody.
- humanized antibody is meant an antibody which contains CDRs regions derived from an antibody of non-human origin, the other parts of the antibody molecule being derived from one (or more) human antibodies.
- some of the skeletal segment residues (referred to as FR) can be modified to maintain binding affinity (Jones et al., 1986, Verhoeyen et al., 1988, Riechmann et al., 1988).
- the humanized antibodies according to the invention may be prepared by techniques known to those skilled in the art such as “CDR grafting", “resurfacing”, Superhumanization, "Human string content", “FR libraries” technologies.
- » « FR shuffling "and” Humaneering as summarized in the review of Almagro et al.
- human antibody is understood to mean an antibody whose entire sequence is of human origin, that is to say whose coding sequences have been produced by recombination of human genes coding for the antibodies. Indeed, it is now possible to produce transgenic animals (eg mice) that are capable, upon immunization, of producing a complete repertoire of human antibodies in the absence of endogenous production of immunoglobulin (see Jakobovits et al. -1993 (a) and (b), Bruggermann et al., 1993 and Duchosal et al., 1992, US patents 5,591, 669, 5,598,369, 5,545,806, 5,545,807, 6,150,584). Human antibodies can also be obtained from phage display libraries (Hoogenboom et al 1991, Marks et al 1991 Vaughan et al 1996).
- the antibodies can be several isotypes, depending on the nature of their constant region: the constant regions ⁇ , ⁇ , ⁇ , ⁇ and ⁇ correspond respectively to immunoglobulins IgG, IgA, IgM, IgE and IgD.
- the monoclonal antibody present in a composition used as a medicament in the context of the invention is of IgG isotype.
- this isotype shows an ability to generate ADCC activity ("Antibody-Dependent Cellular Cytotoxicity", or antibody-dependent cellular cytotoxicity) in the largest number of individuals (humans).
- the constant regions ⁇ comprise several subtypes: ⁇ 1, ⁇ 2, ⁇ 3, these three types of constant regions having the particularity of fixing the human complement, and ⁇ 4, thus creating the lgG1, IgG2, IgG3, and IgG4 sub-isotypes.
- the monoclonal antibody present in a composition used as a medicament in the context of the invention is of the IgG1 or IgG3 isotype, preferably IgG1.
- the monoclonal antibody composition can be produced by a cell clone, a transgenic non-human animal or a transgenic plant, by technologies well known to those skilled in the art.
- cell clones producing the composition can be obtained by 3 main technologies:
- a heavy and light chain expression vector of the antibody comprises the elements necessary for the expression of the sequences coding for the heavy and light chains of the antibody, and in particular a promoter, a codon for initiation of transcription, termination sequences, and appropriate transcriptional regulatory sequences. These elements vary according to the host serving for the expression and are readily selected by those skilled in the art in view of his general knowledge.
- the vector may especially be plasmidic or viral. Transformation techniques are also well known to those skilled in the art.
- Transformation of cell lines by one or more expression vectors of the sequences coding for the heavy and light chains of the antibody is the most commonly used, in particular for obtaining chimeric or humanized antibodies.
- the transformed cell line is preferably of eukaryotic origin, and may in particular be chosen from insect, plant, yeast or mammalian cells.
- the antibody composition can then be produced by culturing the host cell under appropriate conditions.
- Cell lines suitable for the production of antibodies include the lines selected from: SP2 / 0; YB2 / 0; IR983F; human myeloma Namalwa; PERC6; the CHO lines, in particular CHO-K-1, CHO-Lec10, CHO-Lec1, CHO-Lec13, CHO Pro-5, CHO dhfr-, or CHO line deleted for the two alleles coding for the FUT8 gene and / or the gene GMD; Wil-2; Jurkat; Vero; Molt -4; COS-7; 293-HEK; BHK; K6H6; NSO; SP2 / 0-Ag 14, P3X63Ag8.653, embryonic duck cell line EB66® (Vivalis); and
- a transgenic non-human animal can be obtained by direct injection of the gene (s) of interest (here, the rearranged genes encoding the heavy and light chains antibody) in a fertilized egg (Gordon et al. 1980).
- a transgenic non-human animal can also be obtained by introducing the gene (s) of interest (here, the rearranged genes encoding the heavy and light chains of the antibody) into an embryonic stem cell and preparing it. animal by a chimera aggregation method or a chimeric injection method (see Manipulating the Mouse Embryo, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994), Gene Targeting, A Practical Approach, IRL Press at Oxford University Press (1993)).
- a transgenic non-human animal can also be obtained by a cloning technique in which a nucleus, in which the gene (s) of interest (here, the rearranged genes encoding the heavy and light chains of the antibody) has been introduced, is transplanted into an enucleated egg (Ryan et al 1997, Cibelli et al., 1998, WO0026357A2).
- a transgenic non-human animal producing an antibody of interest can be prepared by the above methods. The antibody can then be accumulated in the transgenic animal and harvested, in particular from the milk or eggs of the animal.
- Non-human transgenic animals of interest include mice, rabbits, rats, goats, cattle (including cows), and poultry (especially chicken).
- the antibody composition can be produced in a transgenic plant.
- Many antibodies have already been produced in transgenic plants and the technologies necessary to obtain a transgenic plant expressing an antibody of interest and to the recovery of the antibody are well known to those skilled in the art (see Stoger et al-2002, Fisher et al. 2003, Ma et al. 2003, Schillberg et al. 2005). It is also possible to influence the glycosylation obtained in the plants to obtain glycosylation close to that of natural human antibodies (without xylose), but with, in addition, low fucosylation, for example with the aid of small interfering RNAs (Forthal et al. al, 2010).
- step b) of the process for obtaining a monoclonal antibody composition intended to be used as a medicament according to the invention the different antibody loading isoforms present in the composition obtained in step a) are separated by fractionation of the composition obtained in step a) by chromatography.
- any monoclonal antibody composition produced by a cell clone, a non-human transgenic animal or a transgenic plant is characterized by the presence of a number of isoforms or charge variants of the same monoclonal antibody.
- Each isoform or charge variant is characterized by its isoelectric point (p1, also called isoelectric hydrogen potential (pHI)), which corresponds to the pH (hydrogen potential) for which the overall charge of this molecule is zero or, in other words, the pH for which the molecule is electrically neutral (zwitterionic form or mixed ion).
- p1 isoelectric point
- pHI isoelectric hydrogen potential
- the different isoforms or charge variants of a monoclonal antibody will therefore have variable net charges, those whose pl is below the pH carrying a negative charge (the molecule tends to give its protons to the basic medium), those whose pH is equal to pH being neutral, and those whose pH is higher than the pH carrying a positive charge (the molecule tends to conserve its protons or to capture acidic medium).
- the different isoforms or charge variants of a monoclonal antibody are present in varying proportions, depending on the frequency of post-translational modifications present on each variant.
- a monoclonal antibody composition generally comprises a major variant or isoform, accompanied by a plurality of so-called acidic or basic variants or isoforms, depending on whether their p1 is lower or higher than that of the majority isoform.
- the proportions of the acid isoforms, the majority peak and the basic isoforms (calculated from the chromatogram of an ion exchange chromatography) , generally vary around the following values: 10 to 30% of acid isoforms, 50 to 75% of dominant peak, and 8 to 20% of basic isoforms (see Farnan et al. 2009, Rea et al-201 1, Rea and al-2012, Khawli et al., 2010, Zhang et al. 201 1, WO201 1/009623, and EP1308456).
- the antibody loading isoforms present in a given antibody composition can be separated by different chromatography technologies.
- Chromatography is a technique for separating chemical substances (homogeneous liquid or gaseous mixture) based on differences in behavior between a current mobile phase and a stationary phase (or fixed phase). Chromatographic methods can be classified according to the nature of the phases used or the phenomena used in the separation.
- the fractionation of step b) is carried out using ion exchange chromatography. This makes it possible to separate the charge isoforms of the same protein.
- ion exchange chromatography anions or cations
- the parameter that will allow the separation of the various constituents is their net charge.
- the antibody composition is first loaded onto an ion exchange resin.
- resins stationary or stationary phase
- anion exchange chromatography or negatively (cation exchange chromatography).
- charge molecules opposite to that of the resin ions will be retained / fixed on the resin.
- any type of strong or weak cation or anion exchange resin known to those skilled in the art and suitable for the separation of the antibody composition of interest may be used.
- the average isoelectric point (pI) of an antibody composition generally varies between 5 and 9, most often between 7 and 9.
- a cation exchange resin is used for a pI greater than 8
- an anion exchange resin is used for a pI less than 6, an anion exchange resin is used for a pI between 6 and 8, both types of ion exchange resins (cations or anions) can be tested.
- anion exchange chromatography negatively charged resin
- anion exchange chromatography charged resin positively.
- the ion exchange resins generally consist of a crosslinked polymer or gel, on which positively charged (anion exchange resin) or negatively (cation exchange resin) groups are grafted.
- the crosslinked polymer or gel may especially be chosen from dextran (eg Sephadex®), agarose (eg Sepharose®), cellulose, methacrylate polymers (eg Fratogel®), vinyl polymers (eg Fractoprep ®) such as poly (styrene divinylbenzene) (eg Monobeads TM, Source TM, Bio Mab NP-5 or NP-10, Sepax Antibodix TM NP1.7, NP3, NP5 and NP10).
- the gel may advantageously be in the form of beads, with a mean diameter of between 10 and 200 ⁇ .
- cation exchange resins negatively charged groups are grafted onto the crosslinked polymer, such as sulfopropyl (SP), methyl sulfonate (S) or carboxymethyl (CM) groups.
- positively charged groups are grafted on the crosslinked polymer, such as quaternary ammonium groups (Q), especially aminoethyl quaternary (QAE), diethylaminoethyl (DEAE), dimethylaminoethyl (DMAE), trimethylaminoethyl (TMAE), or dimethylaminopropyl (ANX).
- Q quaternary ammonium groups
- Q quaternary ammonium groups
- QAE aminoethyl quaternary
- DEAE diethylaminoethyl
- DMAE dimethylaminoethyl
- TMAE trimethylaminoethyl
- ANX dimethylaminopropyl
- Cation exchange resins suitable for use in the present invention include Source TM 15S or 30S, Mono-S resins (commercially available from GE Life Sciences); ProPac® WCX (in particular ProPac® WCX-10), ProPac® SCX (in particular ProPac® SCX-10 or SCX-20), ProSwift WCX, MAbPac® SCX (in particular MAbPac® SCX-10) (marketed by Dionex) ; Bio Mab (in particular Bio Mab NP-5 or NP-10, marketed by Agilent), PL-SCX (marketed by Agilent); Sepax Antibodix TM (in particular Sepax Antibodix TM NP1.7, NP3, NP5 and NP10) (marketed by Sepax) (see Farnan et al.
- ProPac® WCX in particular ProPac® WCX-10
- ProPac® SCX in particular ProPac® SCX-10 or SCX-20
- anion exchange resins suitable for use in the present invention include Source TM 15Q or 30Q, Mono TM -Q resins (commercially available from GE Life Sciences); ProPac® WAX (in particular ProPac® WAX-10), ProPac® SAX (in particular ProPac® SAX-10) (marketed by Dionex).
- the elution of the fixed molecules may in particular be carried out using an elution buffer (mobile phase) containing ions of charge opposite to that of the resin ions, which will compete with the molecules fixed to interact with the charged charges. by the resin.
- an elution buffer mobile phase
- ions of charge opposite to that of the resin ions which will compete with the molecules fixed to interact with the charged charges. by the resin.
- the elution is carried out not with the aid of an ionic strength gradient, but with the aid of a pH gradient.
- many ionizable groups are sensitive to pH. With an ascending gradient of pH (i.e. increasing the pH), the ionization of the acid groups (negatively charged) is favored and the ionization of the basic groups (positively charged) is unfavorable. By increasing the pH, the appearance of a net negative charge is therefore favored for the molecules carrying pH-sensitive ionizable groups.
- An ascending pH gradient thus also makes it possible to separate the charge isoforms of an antibody composition fixed on a negatively charged resin (cation exchange). With a descending gradient of pH (i.e.
- Rea et al-2012 also describes the principle of this technology, as well as how to appropriately select the column, buffers and operation parameters for separating isoforms or antibody load variants (see section 8, pages 451 -452).
- Example 1 also describes the separation of charge isoforms from an antibody composition by cation exchange chromatography and elution by an ascending pH gradient.
- the elution can also be carried out by the combination of an ionic strength gradient and a pH gradient ("hybrid" elution), as described in Rea et al. -2012 (see section 9 page 453).
- an ion exchange resin (anions or cations) is also used as a stationary or stationary phase, but elution is not performed using a force gradient ionic and / or pH, but using a displacement molecule, that is to say a molecule with a high affinity for the chromatography resin, which will compete for the fixation on the resin with the antibody molecules previously fixed on the resin, and thus move the antibody molecules having a lower affinity for the resin than the displacement molecule.
- the antibody molecules are thus forced to migrate along the column by a wave of displacement molecule.
- any elution buffer pH gradient or ionic strength
- appropriate displacement may be used, depending on the chosen column.
- resins and associated buffers are described in Farnan et al. 2009, Khawli et al. 2010, Lucas et al. 201, Zhang et al. 201, Rea et al. 201, and McAtee et al.
- Another chromatographic technique that separates the charge isoforms from an antibody composition is chromatofocusing.
- the proteins are separated according to their isoelectric point (p1).
- This technique relies on the use of the combination of a particular resin (fixed or stationary phase) and a particular amphoteric buffer.
- obtaining a linear gradient of pH requires an equal buffer capacity over the entire pH range used for the separation, hence the need for buffers designed specifically for this application and resins substituted with charged buffer amines.
- the principle of separation is as follows: a chromatofocusing resin is equilibrated with a starting buffer at a pH slightly higher than the highest required pH. An elution buffer (adjusted to the lowest pH required) is passed through the column and begins to titrate the amines of the resin and proteins. As the elution buffer passes through the column, the pH is decreased and a descending and moving gradient of pH is generated. The sample is applied to the column after a first volume of elution buffers is passed over the column. The proteins in the sample are titrated (pH adjustment) as soon as that they are introduced in the column. Those that are at pH above their p1 are negatively charged and retained near the top of the column (by binding to positively charged amino groups). Proteins that are at a pH below their pI begin to migrate along the column with the buffer flow and will not bind to the column before reaching an area where the pH is greater than their pI. This is the beginning of the separation process.
- proteins with different pIs migrate at different rates across the column as the pH gradient develops, binds, and continuously dissociates from the positively charged amino-bearing resin. by being gradually focused into narrow bands and finally eluted. Proteins with the highest pH are eluted first, while protein with the lowest pH is eluted last.
- the resin used for separation by chromatofocusing is based on a conventional resin (crosslinked polymer or gel as described above, preferably in the form of beads as described above), in particular of the poly (styrene divinylbenzene) or agarose type. crosslinked, which is characterized by the grafting of positively charged amino groups. These amino groups positively charged buffers are especially secondary, tertiary and / or quaternary amine groups.
- resins useful in chromafocalization include Mono TM -P (crosslinked poly (styrene divinylbenzene) grafted with secondary, tertiary and / or quaternary amine groups), PBE 94 and PBE 1 18 (crosslinked 6% agarose resins).
- the Mono TM -P and PBE 94 columns are suitable for separation between pH 9 and pH 4, while the PBE 1 18 column is suitable for separation with a pH gradient starting above pH 9.
- the Mono TM columns -P and PBE 94, and in particular the Mono TM -P column, are preferred.
- the starting buffers used may in particular be based on a solution of diethanolamine, Tris, triethanolamine, bis-Tris, triethylamine, ethanolamine, imidazole, histidine, or piperazine at different pH (addition of a type of acid HCI, acetic acid, or iminodoacetic acid).
- amphoteric elution buffers used include Polybuffer 74 (pH range: 7-4, for Mono TM -P and PBE 94 columns), Polybuffer 96 (pH range: 9-6, for Mono TM columns -P and PBE 94), and Pharmalyte pH8-10.5 (pH range: 1-18, for PBE column 1 18).
- step b) of the method for obtaining a monoclonal antibody composition intended to be used as a medicament according to the invention the fractionation of step a) is carried out by one of the following chromatography techniques:
- step b) of the method for obtaining a monoclonal antibody composition intended to be used as a medicament according to the invention the fractionation of step a) is carried out by one of the following techniques: following chromatography:
- the inventors have been able to separate the isoforms or charge variants of a monoclonal antibody composition by two different techniques that may be used in the context of the invention:
- the chromatogram of an antibody composition obtained by chromatographic technology for separating the charge isoforms still comprises a major peak comprising the major charge isoform as well as other isoforms close to the major isoform (this is that is to say with few modifications compared to the majority isoform and therefore a pl and a net charge at a given pH very close to that or that of the majority isoform), surrounded by minority peaks comprising on the one hand the isoforms called "acid”, whose pl is lower compared to the major isoform, and on the other hand the so-called "basic” isoforms, whose pl is greater than the majority isoform (see Figures 1-2) .
- the different isoforms appear on the chromatogram and are eluted in the following order: • Use of cation exchange chromatography (negatively charged resin), whatever the elution mode (elution by ionic gradient, pH gradient, Ph gradient and ionic strength or by a molecule of displacement): the acidic isoforms (which are less positively charged than the major isoform) are eluted first, followed by the major isoform, then basic isoforms (which are more positively charged than the majority isoform) (see Figure 1).
- Chromatofocusing the basic isoforms are eluted first, followed by the major isoform, then acid isoforms (see FIG. 1 of the present description);
- the isoforms or charge variants of an antibody present in an antibody composition produced by a cell clone, a non-human transgenic animal or a transgenic plant may also be separated by other technologies than chromatography. However, if these technologies are very useful for the purpose of analysis or characterization of the isoforms or charge variants, they do not allow these isoforms to be separated with an acceptable yield and are therefore little used for a preparative purpose.
- isoelectric focusing (so-called “IEF” for "Isoelectric focusing”, and also called electrofocusing).
- FIE isoelectric focusing
- the basic principle of isoelectric focusing (FIE) is to create in a gel (possibly included in a capillary) a pH gradient in which the proteins subjected to an electric field can move. The proteins will migrate in this electric field. Arrivals at the pH corresponding to their pl, they will stop because their net charge will be zero. In this way, it is possible to separate the proteins of a preparation according to their pl.
- Such a pH gradient can be created with polyelectrolytes bearing a certain number of positively or negatively ionizable groups (amines, carboxyls or sulphates) and possessing a certain buffering power. These molecules are called ampholytes. If these ampholytes are subjected to an electric field bounded by a solution of a strong acid at the anode and by a solution of a strong base at the cathode, they will migrate and be distributed in order of pl. Their buffering capacity will help to maintain around them a small zone of pH equal to their pl. A series of ampholytes each having a pl covering a certain pH range will therefore create a continuous pH gradient. If a small amount of protein is migrated into this system, after or during training, they will also migrate and become immobile.
- agarose As an inert matrix for the gel, it is possible to use agarose, acrylamide or, more rarely, dextran, in which the pH gradient will be formed. A polyacrylamide gel is most often used. Since only pI must influence migration, it is necessary to use acrylamide concentrations whose porosity will not slow down large proteins compared to small ones, but is sufficiently strong to be easily handled. A gel of 5-6% is usually the case.
- the anode buffer is a strong acid, usually phosphoric acid.
- a strong base is placed, often triethanoamine.
- Ampholytes are included in the gel preparation mixture prior to polymerization. These molecules, which are polyelectrolytes, move in the electric field and arrange themselves one after the other in the order of their own pl. Many companies manufacture a large number of ampholyte mixtures covering very narrow or very wide ranges of pH: Ampholine® (including Ampholine® pH 6/8 and Ampholine® pH 7/9 marketed by Sigma Aldrich), Pharmalyte® (particularly Pharmalyte® pH 8 / 10.5 sold in particular by Sigma Aldrich and GE Healthcare, Life Sciences), BioLite® (in particular BioLite® pH 6/8, BioLite® pH 7/9 and BioLite® pH 8/10 marketed by Bio-Rad ), Zoom® (including Zoom® pH 6/9 marketed by Life Technologies / Invitrogen), Servalyt TM (including Servalyt TM pH 6/8, Servalyt TM pH 6/9, Servalyt TM pH 7/9 marketed by Serva), SinuLyte
- each ampholyte When a voltage is applied between the two electrodes, each ampholyte will move to its isoelectric point and become immobilized there. Gradients of various pH amplitudes can be created by combining various ampholytes.
- gradients with very small intervals eg 0.1 pH unit
- the antibody composition to be analyzed may be added after polymerization of the gel or directly into the mixture prior to polymerization. Since the antibodies are larger than the ampholytes, they will migrate much more slowly and the ampholytes will therefore be able to stabilize well before the antibodies have moved substantially.
- the duration of the migration is not critical. Indeed, the antibodies are not likely to come out of the gel since they will stop at the point where they have reached their pl. It is only necessary that the migration lasts long enough for the ampholytes to have the time to migrate properly and that the antibodies have time to reach their pl. At 2 mA, the estimated time required is about 1 hour.
- the gel may be stained to analyze the different charge isoforms present in the antibody composition. Staining can be performed by any conventional technique used in conventional electrophoresis. However, ampholytes must be removed from the gel as they may become stained. Thus, the staining is usually preceded by soaking in a 5 or 10% trichloroacetic acid bath to diffuse out of the gel while fixing the antibodies on the spot.
- markers possessing a given p1 makes it possible to determine quite precisely the p1 of the different isoforms of charge.
- the proportion in the analyzed composition of each IEF separated charge isoform relative to the total isoforms can be quantified using image analysis software, such as the Quantity One® software, for example. by Bio-Rad.
- the isoelectric focusing technology does not allow easy harvesting of the separated isoforms and is therefore generally used for analysis and quantification purposes. for purposes of preparative separation of different isoforms.
- step c) of the process the composition of interest according to the invention, intended to be used as a medicament, is obtained by grouping one or more chromatographic fractions obtained in step b), corresponding to the peak majority of the chromatogram, the monoclonal antibody composition thus obtained being enriched in said majority peak, the latter representing at least 85%, advantageously at least 86%, at least 87%, at least 88%, at least 89%, more at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95%, at least 96%, at least 97%, at least at least 98%, at least 98.5%, at least 99%, or at least 99.5% of the chromatogram of the composition obtained in step c).
- a composition for use as a medicament at least 95%, advantageously at least 96%, at least 97%, at least 98%, or even at least 98.5%, at least 99% or at least 99.5% of the heavy chains of the antibodies present in the composition do not include a C-terminal lysine residue.
- the invention also relates to a monoclonal antibody composition, wherein at least 95%, preferably at least 96%, at least 97%, at least 98%, or at least 98.5%, at least 99%, or at least less than 99.5% of the heavy chains of the antibodies present in the composition do not comprise a C-terminal lysine residue for use as a medicament.
- the basic isoforms of the antibodies present in the composition have at least one heavy chain with a C-terminal lysine residue.
- Such a composition thus comprises only the major isoform and acid isoforms. Since the basic isoforms are not very active for the effector functions via Fc ⁇ RIII and via the complement (see Examples) and represent before purification approximately 8 to 20% (measured by chromatography), such a composition is capable of inducing a stronger ADCC via Fc ⁇ RIII and a stronger CDC response than the total composition, before excluding basic isoforms.
- Such a composition can be obtained by chromatographic separation as described above, but the collected fractions corresponding in this case to those of the acid and majority isoforms.
- the antibody composition obtainable by the process described above and intended to be used as a medicament may be used in any pathology that may be treated with monoclonal antibodies, in particular when the destruction of target cells by ADCC or CDC is useful for treatment.
- ADCC Alzheimer et al.
- 1994, Velders et al. 1998, Cartron et al 2002, lanello et al-2005, Weiner et al-2010 the prevention of alloimmunization in Rh-negative pregnant women
- Béliard et al-2008 the ADCC response is also known to play an important role in the anti-infectious response against viruses (Ahmad et al. 1996, Miao et al. (Albrecht et al 2007, Casadevall et al 2002) and parasites (Zeitlin et al 2000).
- new therapies aim to eliminate the immune cells responsible for the attacks, such as B or T lymphocytes for example, the ADCC then playing a very important role (Edwards et al-2006; et al-2010).
- the CDC response is also known to be important in various pathologies and in particular in the treatment of cancers.
- the antibody is advantageously directed against a non-ubiquitous antigen present on healthy donor cells, an antigen of a cancer cell, an antigen of a cell infected with a pathogen, or an antigen from an immune cell.
- the antibody is an anti-Rhesus D antibody (in particular Roledumab, Atorolimumab or Morolimumab, in particular Roledumab) and the composition is intended for the prevention of alloimmunisation in Rh-negative individuals,
- the antibody is directed against an antigen of a cancer cell and the composition is for the treatment of cancer
- the antibody is directed against an antigen of a cell infected with a pathogenic agent and the composition is intended for the treatment of an infection by said pathogenic organism,
- the antibody is directed against an antigen of an immune cell and the composition is for the treatment of an autoimmune disease.
- the antibodies can in particular be directed against the following antigens: CD20, Her2 / neu, CD52, EGFR, EPCAM, CCR4, CTLA-4 (CD152), CD19, CD22, CD3, CD30, CD33, CD4, CD40, CD51 (Integrin alpha-V), CD80, CEA, FR-alpha, GD2, GD3, HLA-DR, IGF1 R (CD221), phosphatidylserine, SLAMF7 (CD319), TRAIL-R1, TRAIL-R2.
- Hematologic cancers rituximab, ofatumumab,
- Solid cancers including:
- lymphocytic leukemia Hematologic cancers, including lymphocytic leukemia
- Solid tumors including:
- colorectal cancer head cancer Futuximab, Imgatuzumab,
- stomach glioma, astrocytoma Zalutumumab
- Solid cancers including:
- CCR4 Mogamulizumab including: Leukemia / adult T-cell lymphoma
- CD152 Hematological cancers
- Visilizumab in particular: multiple myeloma
- CD33 Lintuzumab in particular: acute myeloid leukemia, myelodysplastic syndromes
- Cedelizumab Cedelizumab, Clenoliximab, Melanoma, T cell lymphoma
- Dacetuzumab in particular: non-lymphoma
- Lucatumumab Hodgkin's Teneliximab, Hodgkin's Lymhoma, Multiple Myeloma
- B cell lymphoma including: B cell lymphoma
- Solid tumors including:
- HLA-DR Apolizumab Hematologic cancers
- Solid tumors including:
- IGF1 R non-small lung cancer
- CD221 cells, adenocortical carcinoma
- pancreatic cancer Solid tumors including:
- Solid tumors including:
- Solid tumors including:
- the antibodies may in particular be directed against the following antigens: antigens of Clostridium difficile, antigens of Staphylococcus aureus (in particular ClfA and lipotheicoic acid), antigens of cytomegalovirus (in particular glycoprotein B), Escherichia coli antigens (including Shiga-like toxin, MB subunit), Respiratory syncytial virus antigens (Protein F in particular), Hepatitis B virus antigens, Influenza A virus antigens (including haemagglutinin), Pseudomonas antigens aeruginosa serotype IATS 01 1, antigens of rabies virus (Glycoprotein in particular), phosphatidylserine
- Clostridium difficile infection Clostridium difficile Bezlotoxumab ClfA antigen
- glycoprotein B glycoprotein B
- the antibodies can in particular be directed against the following antigens: CD20, CD52, CD25, CD2, CD22, CD3, and CD4. More specifically, specific pairs (antigen / autoimmune disease) known for their therapeutic interest (antibodies of this antigenic specificity approved in at least one country for the treatment of the aforementioned autoimmune disease, or clinical trials in progress) are indicated in Table 3. below.
- Antibody compositions for use as a medicine according to the invention are particularly intended for therapies involving an ADCC response, which includes many cases as explained in detail above. It is therefore advantageous that these antibodies have also been optimized by other means to induce an in vivo ADCC response via the strongest possible FcyRIII receptor.
- the antibody in a composition for use as a medicament according to the invention, comprises a modification of the Fc fragment increasing its binding to the Fc ⁇ RIII receptor and its effector properties via the Fc ⁇ RIII receptor.
- a composition for use as a medicament according to the invention comprises a monoclonal antibody whose sequence has been modified at at least one amino acid residue of the Fc fragment to increase the binding to the Fc ⁇ RIII receptor, as described in WO00 / 42072, Shields et al-2001, Lazar et al. 2006, WO2004 / 029207, WO / 2004063351, WO2004 / 074455.
- mutations at the following positions of Fc have been described as allowing to increase the affinity for the FcyRI II receptor and the ability to induce an ADCC via this receptor: 219, 222, 224, 239, 247, 256, 267 , 270, 283, 280, 286, 290, 294, 295, 296, 298, 300, 320, 326, 330, 332, 333, 334, 335, 339, 360, 377, 396.
- Combinations of interesting mutations include: E333A / K334A, T256A / S298A, S298A / E333A, S298A / K334A, S298A / E333A / K334A, S267A / D280A (WO00 / 42072), S239D / I332E, S239D / I332E / A330L (Lazar and al-2006), V264I / I332E, S298A / I332E, S239E / I332E, S239Q / I332E, S239D / I332D, S239D / I332E, S239D / I332N, S239D / I332Q, S239E / I332D, S239E / I332N, S239N / I332E, S239Q / I332D, A330Y / I
- a monoclonal antibody composition for use as a medicament according to the invention comprises a low fucose content.
- fucose content is meant the percentage of fucosylated forms within the N-glycans attached to the Asn297 residue of the Fc fragment of each heavy chain of each antibody.
- low fucose content is meant a fucose content less than or equal to 65%.
- the fucose content is less than or equal to 65%, preferably less than or equal to 60%, 55% or 50%, or even less than or equal to 45%, 40%, 35% or 30%. , 25% or 20%. However, it is not necessary that the fucose content be zero, and it may for example be greater than or equal to 5%, 10%, 15% or 20%.
- the fucose content can for example be between 5 and 65%, between 5 and 60%, between 5 and 55%, between 5 and 50%, between 5 and 45%, between 5 and 40%, between 5 and 35% between 5 and 30%, between 5 and 25%, between 5 and 20%, between 10 and 65%, between 10 and 60%, between 10 and 55%, between 10 and 50%, between 10 and 45%, between 10 and 40%, between 10 and 35%, between 10 and 30%, between 10 and 25%, between 10 and 20%, between 15 and 65%, between 15 and 60%, between 15 and 55%, between 15 and 50%, between 15 and 45%, between 15 and 40%, between 15 and 35%, between 15 and 30%, between 15 and 25%, between 15 and 20%, between 20 and 65%, between 20 and 60% between 20 and 55%, between 20 and 50%, between 20 and 45%, between 20 and 40%, between 20 and 35%, between 20 and 30%, between 20 and 25%.
- the antibody composition may furthermore possess different types of glycosylation (oligomannose-type N-glycans or biantennary complexes, variable proportion of N-acetylglucosamine residues (GIcNAc)) or galactose residues in the case of N-glycans of the biantennary complex type. ), provided that it has a low fucose content.
- glycosylation oligomannose-type N-glycans or biantennary complexes, variable proportion of N-acetylglucosamine residues (GIcNAc)) or galactose residues in the case of N-glycans of the biantennary complex type.
- oligomannose-type N-glycans can be obtained by culturing in the presence of different glycosylation inhibitors, such as the inhibitors of ⁇ 1,2-mannosidase I (such as Deoxymannojirimycin or "DMM”) or ⁇ -glucosidase (such as castanospermine or "Cs"); or by production of the antibody in the CHO Lec 1 line.
- different glycosylation inhibitors such as the inhibitors of ⁇ 1,2-mannosidase I (such as Deoxymannojirimycin or "DMM") or ⁇ -glucosidase (such as castanospermine or "Cs"); or by production of the antibody in the CHO Lec 1 line.
- N-glycans of the biantennen complex type can be obtained in most mammalian cells, but also in bacteria, yeasts or plants whose glycosylation machinery has been modified.
- lines naturally possess a low activity of the FUT8 (1, 6-fucosyltransferase) enzyme responsible for the addition of fucose to the Fc-linked GIcNAc; such as the YB2 / 0 line, the EB66® duck embryonic cell line, or the rat rat H4-II-E hepatoma lines (DSM ACC3129), H4-ll-Es (DSM ACC3130); can be used.
- Mutant lines for other genes whose subexpression or overexpression leads to a low fucose content may also be used, such as the CHO Lec13 line, a mutant of the CHO line having decreased GDP-fucose synthesis.
- N-glycans notably FUT8, see Yamane-Ohnuki et al-2004, but also GMD, a gene involved in the transport of GDP-fucose, see Kanda et al-2007.
- Another alternative is to select a line of interest and overexpress a protein interfering in one way or another with the fucosylation of N-glycans, such as the protein GnTIII ( ⁇ (1,4) -N-acetylglucosaminetransferase III ).
- GnTIII ⁇ (1,4) -N-acetylglucosaminetransferase III
- Oligomannose N-glycans have a reduced half-life in vivo compared to biantennane-type N-glycans. Therefore, advantageously, the antibodies present in the composition have, at their N-glycosylation sites of the Fc fragment, glycan structures of the bantennate complex type, with a low fucose content, as defined above.
- the monoclonal antibody composition may have a content of G0 + G1 + G0F + G1 F greater than 60% and a low fucose content as defined above. It may also have a G0 + G1 + G0F + G1 F content content greater than 65% and a low fucose content, as defined above. It may also have a G0 + G1 + G0F + G1 F content content greater than 70% and a low fucose content, as defined above. It may also have a G0 + G1 + G0F + G1 F content content greater than 75% and a low fucose content, as defined above.
- G0 + G1 + G0F + G1 F content content greater than 80% and a low fucose content, as defined above. It may also have a G0 + G1 + G0F + G1 F content content greater than 60%, 65%, 70%, 75% or 80% and a G0F + G1 F content content of less than 50%.
- the forms G0, G1, G0F and G1 F are as defined below:
- Such antibody compositions can in particular be obtained by production in YB2 / 0, in CHO Lec13, in wild-type CHO lines cultured in the presence of small interfering RNAs directed against FUT8 or GMD, in CHO lines including the two alleles of the FUT8 gene. coding for the 1, 6- fucosyltransferase or the two alleles of the GMD gene encoding the GDP-fucose transporter in Golgi were deleted.
- Antibody compositions for use as a medicine according to the invention are also intended for therapies involving a CDC response. It may therefore also be advantageous, in addition to or alternatively to modifications increasing the activity via Fc ⁇ RIII, that these antibodies have also been optimized by other means to induce a CDC response in vivo via the strongest C1 protein q possible.
- the antibody in a composition for use as a medicament according to the invention, comprises a modification of the Fc fragment increasing its binding to C1 protein and its effector properties via complement.
- the present invention also relates to the use of a chromatographic fractionation step to increase the ability of a monoclonal antibody composition directed against a given antibody to induce antibody-dependent cellular cytotoxicity (ADCC) of target cells expressing said antigen by the effector cells of the immune system expressing the Fc ⁇ RIII receptor (CD16).
- ADCC antibody-dependent cellular cytotoxicity
- the composition thus obtained has an improved ability to induce ADCC of target cells expressing the antigen of interest by the effector cells of the immune system expressing the Fc ⁇ RIII receptor (CD16), and especially by natural killer cells (or NK cells for "Natural killer cells”).
- the ratio R of the ADCC levels obtained with the composition enriched in isoforms of the major peak and with the composition before fractionation defined by the following formula:
- ADCC level obtained with the isoform enriched composition of the majority ADCC rate peak obtained with the composition before fractionation is at least 1.15 (corresponding to an increase in the ADCC level of at least 15%); advantageously at least 1, 16; at least 1, 17; at least 1, 18; at least 1, 19; more preferably at least 1, 20; at least 1.25; at least 1.30; at least 1.35; at least 1.40; at least 1.45; or at least 1.50 (corresponding to an increase in the ADCC rate of at least 50%).
- the present invention also relates to the use of a chromatography fractionation step for increasing the ability of a monoclonal antibody composition directed against a given antibody to induce complement-dependent cytotoxicity (CDC) of target cells expressing said antigen by the complement.
- CDC complement-dependent cytotoxicity
- composition thus obtained has an improved ability to induce complement lysis of target cells expressing the antigen of interest.
- ratio R of the CDC levels obtained with the composition enriched in isoforms of the majority peak and with the composition before fractionation defined by the following formula:
- CDC level obtained with the isoform enriched composition of the majority CDC level peak obtained with the composition before fractionation is at least 1.15 (corresponding to a CDC rate increase of at least 15%); advantageously at least 1, 16; at least 1, 17; at least 1, 18; at least 1, 19; more preferably at least 1, 20; at least 1.25; at least 1.30; at least 1.35; at least 1.40; at least 1.45; at least 1, 50 (corresponding to a CDC rate increase of at least 50%).
- the chromatography fractionation step can be carried out in any of the above described ways to obtain the majority isoform enriched antibody compositions according to the invention for use as a medicament.
- the fractionation can be carried out by one of the following chromatography techniques:
- the monoclonal antibody composition for which such a chromatography fractionation step is performed in order to increase the ADCC or CDC response capabilities via the CD16 expressing effector cells may be any of the monoclonal antibody compositions described above.
- the monoclonal antibody present in the composition may be human, humanized or chimeric.
- the antibody can be directed against a cancer cell antigen, and in particular one of the antigens described above in the context of the treatment of cancers.
- the antibody may be directed against an antigen of the infected cells, and in particular against one of the antigens described above as part of the treatment of infectious diseases.
- the target cells are immune cells involved in the development of an autoimmune disease, the antibody can be directed against an antigen of these immune cells, and in particular against one of the antigens described above in the context of the treatment of autoimmune diseases.
- the fractionation step by chromatography (step a)) is preferably followed by a step of grouping the chromatographic fractions obtained corresponding to the major peak of the chromatogram (step b)), the monoclonal antibody composition thus obtained being enriched in said majority peak, this representing at least 85% of the chromatogram of the composition obtained in step b) (after fractionation and grouping of the chromatographic fractions of interest).
- Mono P 5/200 GL anion exchange resin was used. 20 mg of desalted protein were injected at each separation. Elution was performed using a descending pH gradient (pH 9.5 to 8.0), using the following two buffers:
- Buffer A 25 mM diethanolamine
- Buffer B polybuffer 96 + pharmalyte 8-10.5.
- the eluates from the separations were collected in fractions of 2mL.
- the fractions of interest are fractions 33 to 50.
- Separation 1 has undergone a particular concentration so that the fractions can be rendered sterile by filtration:
- SCX cation exchange resin (MabPac SCX 4x250 mm, Dionex) was used at 30 ° C. Elution was performed using an ascending pH gradient (pH 6 to 10), using the following two buffers:
- Buffer A 20 mM NaH 2 PO 4, 60 mM NaCl (pH 6),
- Buffer B 20 mM Na 2 HPO 4, 60 mM NaCl (pH 10).
- the gradient was obtained as follows: 10% to 60% buffer B in 60 minutes.
- the eluates of the separations were collected in fractions.
- the fractions of interest are fractions 1 to 20. Analysis of CD16 receptor binding by BIACORE
- SPR Surface Plasmon Resonance
- a soluble CD16a receptor was immobilized on the detection chip using amine coupling.
- One flow cell is used for the antibody, the other flow cell is left free to subtract the background noise.
- the antibodies are injected at three concentrations and the kinetic parameters are estimated by performing for each concentration a binding ratio at both the association phase and the dissociation phase.
- the SPR signal expressed in resonance units (RU), represents the association and dissociation of the antibody to the receptor.
- the test used is the following:
- the antibodies are incubated with WIL2-S cells (CD20 positive target cells) and Jurkat CD16 cells (effector cells) (CD16FF genotype).
- WIL2-S cells CD20 positive target cells
- Jurkat CD16 cells effector cells
- IL2 cytokines
- Antibody 50 ⁇ dilutions ranging from 0.156 to 10 ng / ml in IMDM 5% FCS
- WIL2-S cells 50 ⁇ to 6x10 5 / ml in IMDM 5% SVF (ie 30x10 3 cells / 5 ( ⁇ l)
- the WN2-S target cells are cultured in IMDM medium with 10% decomplemented FCS (medium 110). They are subcultured twice a week in 100 ml of media at 0.2 ⁇ 10 6 cells / ml in an F175 flask. The test is performed on transplanted cells for 24 to 72 hours, and repeated at 1. 10 6 cells / ml in an IMDM + 5% FCS decomplemented medium (medium 15).
- Human serum (AB human serum obtained by coagulation of whole blood) is thawed on the day it is used. Thawing is carried out at + 4 ° C. After thawing, the serum is diluted to 1 ⁇ 2 in medium 15.
- CelITiter-Blue® (Proméga) is stored at -20 ° C, thawed at room temperature before use.
- the concentration of the antibodies to be studied is adjusted to 1 ⁇ g ml in medium 15.
- concentration of the antibodies to be studied is adjusted to 1 ⁇ g ml in medium 15.
- the cells are deposited directly in the plate after adjustment at 1.10 ° C. / ml and set at 37 ° C.
- the cells and the sample are incubated for 5 minutes with shaking at 37 ° C. before depositing the serum.
- the reading can be delayed the next day by stopping and stabilizing the reaction by adding 25 ⁇ l of 3% SDS.
- the plate is then stored at room temperature.
- the plates are centrifuged for 2 minutes at 125 g. 100 ⁇ of each well is taken and distributed in a black optical plate with transparent backgrounds while maintaining the plate plan.
- the reading of the plate is performed with the fluorescence reader with the following parameters:
- This method involves the use of a bacterial cysteine protease (IdeS, an enzyme that breaks down the immunoglobulins of Streptococcus pyogenes), which specifically cleaves the IgGs under their hinge domain, the heavy chain being cleaved into two 25 kDa fragments respectively constituted by the VH domains. -CH1 and CH2-CH3.
- IdeS an enzyme that breaks down the immunoglobulins of Streptococcus pyogenes
- the fragments are separated by liquid chromatography with an acetonitrile gradient and analyzed by mass spectrometry, by the following protocol:
- fraction purified by chromatofocusing or by CEX were freeze-dried and redissolved in 20 ⁇ l of a digestion buffer (50 mM NaH2PO2 and 150 mM NaCl, pH 6.30), and 100 ⁇ l of IdeS enzyme were added in following the instructions of the enzyme kit (FabRICATOR Kit, Genovis, Lund, Sweden).
- the preparation was incubated at 37 ° C for 1 hour under microwave power at 50 W power (CEM Discover System, CEM, Matthews, NC, USA) to improve hydrolysis.
- a denaturing buffer 8M urea and 0.4M NH 4 HCO 3, pH 8.0
- DTT dithiothreitol
- the eluted species were then analyzed by a QSTAR mass spectrometer (QSTAR XL, Applied Biosystems, Toronto, Canada) operating in a positive ion mode of 500 to 3000 m / z and calibrated according to the procedure described by the manufacturer for renin .
- QSTAR mass spectrometer QSTAR XL, Applied Biosystems, Toronto, Canada
- FIG. 1 The chromatograms of the 3 separations are presented in FIG. 1, which shows that they are perfectly superimposable, thus demonstrating the reproducibility of the chromatofocusing separation method. Due to the use of an anion exchange resin and a descending pH gradient, the basic isoforms are eluted first followed by the major isoform followed by acid isoforms.
- the chromatograms of 1 1 cation exchange chromatographic (CEX) separations of the charge isoforms are shown in FIG. 2. Due to the use of a cation exchange resin, the acid isoforms are eluted first, followed by isoform, followed by basic isoforms.
- CEX cation exchange chromatographic
- Peak 4 (P4, main peak) was reanalyzed to CEX to verify the purification efficiency.
- the percentages of acidic, main and basic isoforms obtained before and after separation by CEX are shown in Figure 3 and Table 4 below, and clearly show the purification efficiency of the main peak.
- the fraction corresponding to the major isoform induces a significantly greater activation of Jurkat CD16 cells than the fractions comprising the acidic or basic isoforms.
- the ability of the different charge isoforms to activate effector cells via CD16 varies significantly, with the major isoform having a significantly improved ability compared to other isoforms to activate CD16 expressing effector cells.
- Activation of Jurkat CD16 cells by a reference composition by the total composition before separation, and by the fractions F36 (basic isoforms), F39 (major isoform), and F43, F44, F48, F49 and F50 (isoforms of more and more acidic) of a separation by chromatofocusing.
- CEX cation exchange chromatography
- the purified fractions by chromatofocusing and the CEX purified fractions were analyzed by LC-MS to characterize the percentage of heavy chains with or without N-terminal lysine.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014230134A AU2014230134A1 (en) | 2013-03-15 | 2014-03-14 | Novel medicaments comprising an antibody composition enriched with predominant charge isoform |
CA2907358A CA2907358A1 (fr) | 2013-03-15 | 2014-03-14 | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
CN201480024699.3A CN105163758B (zh) | 2013-03-15 | 2014-03-14 | 包含富集主要电荷同工型的抗体组合物的药物 |
BR112015023209A BR112015023209A8 (pt) | 2013-03-15 | 2014-03-14 | novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma |
US14/776,725 US20160046722A1 (en) | 2013-03-15 | 2014-03-14 | Novel medicaments comprising an antibody composition enriched with predominant charge isoform |
EP14709977.4A EP2968533A1 (fr) | 2013-03-15 | 2014-03-14 | Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
MX2015012812A MX2015012812A (es) | 2013-03-15 | 2014-03-14 | Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor. |
JP2015562236A JP2016512216A (ja) | 2013-03-15 | 2014-03-14 | 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤 |
KR1020157029822A KR20150132522A (ko) | 2013-03-15 | 2014-03-14 | 주요 전하 아이소폼이 풍부한 항체 조성물을 포함하는 신규 의약품 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1352360A FR3003171B1 (fr) | 2013-03-15 | 2013-03-15 | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
FR1352360 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014140322A1 true WO2014140322A1 (fr) | 2014-09-18 |
Family
ID=48771615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/055179 WO2014140322A1 (fr) | 2013-03-15 | 2014-03-14 | Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160046722A1 (fr) |
EP (1) | EP2968533A1 (fr) |
JP (1) | JP2016512216A (fr) |
KR (1) | KR20150132522A (fr) |
CN (1) | CN105163758B (fr) |
AU (1) | AU2014230134A1 (fr) |
BR (1) | BR112015023209A8 (fr) |
CA (1) | CA2907358A1 (fr) |
FR (1) | FR3003171B1 (fr) |
MX (1) | MX2015012812A (fr) |
WO (1) | WO2014140322A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018007453A1 (fr) * | 2016-07-06 | 2018-01-11 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Mutants fc a activite fonctionnelle amelioree |
EP3498293A1 (fr) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Traitement de maladies monogéniques avec un anticorps anti-cd45rc |
EP3626265A1 (fr) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-cd45rc anti-humains et leurs utilisations |
WO2020152290A1 (fr) | 2019-01-23 | 2020-07-30 | Encefa | Compétiteurs de cd31 et utilisations associées |
WO2023041717A1 (fr) | 2021-09-16 | 2023-03-23 | Aboleris Pharma | Domaines de liaison anti-cd45rc humaine et leurs utilisations |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323081B2 (en) * | 2011-07-06 | 2019-06-18 | Genmag A/S | Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains |
WO2017192093A1 (fr) | 2016-05-04 | 2017-11-09 | Delaval Holding Ab | Cartouche pour gobelet trayeur, et gobelet trayeur |
CN113874720A (zh) * | 2019-05-23 | 2021-12-31 | 瑞泽恩制药公司 | 抗体结构域特异性电荷变异体的表征分析 |
CN114829407A (zh) * | 2019-09-23 | 2022-07-29 | 南开大学 | 利用哺乳动物展示筛选FcγR特异性结合Fc |
CN114236010A (zh) * | 2021-12-18 | 2022-03-25 | 苏州莱奥生物技术有限公司 | 一种生物活性药物的药代动力学分析方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006099875A1 (fr) * | 2005-03-23 | 2006-09-28 | Genmab A/S | Anticorps diriges contre cd38 pour le traitement du myelome multiple |
WO2013004841A1 (fr) * | 2011-07-06 | 2013-01-10 | Genmab A/S | Modulation de la cytotoxicité dépendante du complément par des modifications de l'extrémité c-terminale des chaînes lourdes d'anticorps |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0104865A3 (en) * | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
BRPI0314814C1 (pt) * | 2002-09-27 | 2021-07-27 | Xencor Inc | anticorpo compreendendo uma variante de fc |
SI1558648T1 (sl) * | 2002-10-17 | 2012-05-31 | Genmab As | Človeška monoklonalna protitelesa proti CD |
EP2368578A1 (fr) * | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés |
FR2861078B1 (fr) * | 2003-10-16 | 2007-09-21 | Lab Francais Du Fractionnement | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
-
2013
- 2013-03-15 FR FR1352360A patent/FR3003171B1/fr not_active Expired - Fee Related
-
2014
- 2014-03-14 AU AU2014230134A patent/AU2014230134A1/en not_active Abandoned
- 2014-03-14 MX MX2015012812A patent/MX2015012812A/es unknown
- 2014-03-14 BR BR112015023209A patent/BR112015023209A8/pt not_active Application Discontinuation
- 2014-03-14 CA CA2907358A patent/CA2907358A1/fr not_active Abandoned
- 2014-03-14 WO PCT/EP2014/055179 patent/WO2014140322A1/fr active Application Filing
- 2014-03-14 EP EP14709977.4A patent/EP2968533A1/fr not_active Withdrawn
- 2014-03-14 JP JP2015562236A patent/JP2016512216A/ja active Pending
- 2014-03-14 KR KR1020157029822A patent/KR20150132522A/ko not_active Application Discontinuation
- 2014-03-14 CN CN201480024699.3A patent/CN105163758B/zh not_active Expired - Fee Related
- 2014-03-14 US US14/776,725 patent/US20160046722A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006099875A1 (fr) * | 2005-03-23 | 2006-09-28 | Genmab A/S | Anticorps diriges contre cd38 pour le traitement du myelome multiple |
WO2013004841A1 (fr) * | 2011-07-06 | 2013-01-10 | Genmab A/S | Modulation de la cytotoxicité dépendante du complément par des modifications de l'extrémité c-terminale des chaînes lourdes d'anticorps |
Non-Patent Citations (3)
Title |
---|
See also references of EP2968533A1 * |
TAYLOR ZHANG ET AL: "Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 1218, no. 31, 17 May 2011 (2011-05-17), pages 5079 - 5086, XP028236720, ISSN: 0021-9673, [retrieved on 20110527], DOI: 10.1016/J.CHROMA.2011.05.061 * |
YI DU ET AL: "Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies", MABS, vol. 4, no. 5, 1 September 2012 (2012-09-01), pages 578 - 585, XP055077895, ISSN: 1942-0862, DOI: 10.4161/mabs.21328 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018007453A1 (fr) * | 2016-07-06 | 2018-01-11 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Mutants fc a activite fonctionnelle amelioree |
EP3481865B1 (fr) * | 2016-07-06 | 2023-09-06 | Laboratoire Français du Fractionnement et des Biotechnologies | Mutants fc à activité fonctionnelle ameliorée |
US11814438B2 (en) | 2016-07-06 | 2023-11-14 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Fc mutants with improved functional activity |
EP4273163A3 (fr) * | 2016-07-06 | 2024-04-03 | Laboratoire Français du Fractionnement et des Biotechnologies | Mutants fc à activité fonctionnelle ameliorée |
EP3498293A1 (fr) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Traitement de maladies monogéniques avec un anticorps anti-cd45rc |
WO2019115791A1 (fr) | 2017-12-15 | 2019-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc |
EP3626265A1 (fr) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-cd45rc anti-humains et leurs utilisations |
WO2020058495A1 (fr) | 2018-09-21 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps anti-cd45rc humain et leurs utilisations |
WO2020152290A1 (fr) | 2019-01-23 | 2020-07-30 | Encefa | Compétiteurs de cd31 et utilisations associées |
WO2023041717A1 (fr) | 2021-09-16 | 2023-03-23 | Aboleris Pharma | Domaines de liaison anti-cd45rc humaine et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
MX2015012812A (es) | 2016-05-09 |
CA2907358A1 (fr) | 2014-09-18 |
BR112015023209A8 (pt) | 2018-01-23 |
JP2016512216A (ja) | 2016-04-25 |
CN105163758A (zh) | 2015-12-16 |
EP2968533A1 (fr) | 2016-01-20 |
KR20150132522A (ko) | 2015-11-25 |
AU2014230134A1 (en) | 2015-10-29 |
BR112015023209A2 (pt) | 2017-07-18 |
US20160046722A1 (en) | 2016-02-18 |
CN105163758B (zh) | 2017-11-17 |
FR3003171A1 (fr) | 2014-09-19 |
FR3003171B1 (fr) | 2015-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014140322A1 (fr) | Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire | |
TWI732176B (zh) | 全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用 | |
TWI751300B (zh) | Il-8 結合抗體及其用途 | |
AU2012361510B2 (en) | Humanized anti-Epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
US20180326058A1 (en) | Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function | |
JP2021534196A (ja) | 抗tigit抗体 | |
US20180171017A1 (en) | Combined use of immune activators | |
WO2016156450A1 (fr) | Anticorps monoclonaux anti-cd303 | |
FR2879204A1 (fr) | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. | |
WO2020027330A1 (fr) | Molécule de liaison à l'antigène contenant deux domaines de liaison à l'antigène liés l'un à l'autre | |
WO2014096672A1 (fr) | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes | |
WO2019115773A1 (fr) | Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc | |
EP3015115A1 (fr) | Agent thérapeutique comprenant un anticorps anti-épiréguline humanisé en tant que principe actif pour carcinome pulmonaire non à petites cellules à l'exception de l'adénocarcinome | |
JP2020500161A (ja) | 抗kir3dl2剤による処置 | |
EP3390452B1 (fr) | Nouvelle utilisation d'un anticorps dirige contre la proteine membranaire cd303 | |
RU2778053C2 (ru) | Антитела к lag3 | |
EP2660324A1 (fr) | Production d'anticorps thérapeutiques sécrétés dans des micro-algues | |
CN117715940A (zh) | 抗trem-1抗体 | |
CN116194486A (zh) | 异二聚体Fc多肽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480024699.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14709977 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2907358 Country of ref document: CA Ref document number: 2015562236 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14776725 Country of ref document: US Ref document number: MX/A/2015/012812 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 241605 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014709977 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157029822 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014230134 Country of ref document: AU Date of ref document: 20140314 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015023209 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015023209 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150914 |